Zoetis stock kpis
Want to see ZTS full AI Analyst Report?
Revenue by Segment
Zoetis reported revenue by segment of $2.39B in Q3 2026, down 3.1% from Q2 2026 and down 0.4% year over year. The highest value was $2.47B in Q2 2026.
Breaks down sales by business lines (for example companion‑animal products, livestock products, vaccines, diagnostics), highlighting whether growth and margins come from higher‑value, recurring treatments or from cyclical livestock markets and signaling product concentration or diversification trends.
Companion Animal remains the dominant, seasonally peaking franchise, but those regular Q2 spikes are masking weakening organic momentum — management attributes recent softness to intensified competition, clinic visit declines and gross‑to‑net investments, which prompted guidance cuts. Livestock has emerged as the steady growth offset, delivering durable, higher‑quality expansion from vaccines and demand tailwinds. Manufacturing & Human Health is immaterial to company growth. Cost cuts and buybacks are protecting EPS, but near‑term upside hinges on stabilizing Companion Animal price realization and containing promotional/generic pressures.
ZTS Revenue by Segment
| Period | Companion Animal | Livestock | Manufacturing and Human Health | Total |
|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | $1.56B | $797.00M | $29.00M | $2.39B |
| Q2 2026Jun 30, 2026 | $1.71B | $731.00M | $29.00M | $2.47B |
| Q1 2026Mar 31, 2026 | $1.52B | $720.00M | $23.00M | $2.26B |
| Q4 2025Dec 31, 2025 | $1.60B | $756.00M | $30.00M | $2.39B |
| Q3 2025Sep 30, 2025 | $1.65B | $725.00M | $23.00M | $2.40B |
| Q2 2025Jun 30, 2025 | $1.79B | $638.00M | $34.00M | $2.46B |
| Q1 2025Mar 31, 2025 | $1.55B | $645.00M | $29.00M | $2.22B |
| Q4 2024Dec 31, 2024 | $1.57B | $726.00M | $21.00M | $2.32B |
| Q3 2024Sep 30, 2024 | $1.61B | $758.00M | $21.00M | $2.39B |
| Q2 2024Jun 30, 2024 | $1.65B | $694.00M | $18.00M | $2.36B |
| Q1 2024Mar 31, 2024 | $1.45B | $720.00M | $20.00M | $2.19B |
| Q4 2023Dec 31, 2023 | $1.45B | $745.00M | $20.00M | $2.21B |
| Q3 2023Sep 30, 2023 | $1.41B | $716.00M | $21.00M | $2.15B |
| Q2 2023Jun 30, 2023 | $1.49B | $671.00M | $20.00M | $2.18B |
| Q1 2023Mar 31, 2023 | $1.23B | $758.00M | $17.00M | $2.00B |
| Q4 2022Dec 31, 2022 | $1.30B | $710.00M | $27.00M | $2.04B |
| Q3 2022Sep 30, 2022 | $1.27B | $708.00M | $23.00M | $2.00B |
| Q2 2022Jun 30, 2022 | $1.37B | $668.00M | $18.00M | $2.05B |
| Q1 2022Mar 31, 2022 | $1.26B | $705.00M | $18.00M | $1.99B |
| Q4 2021Dec 31, 2021 | $1.18B | $760.00M | $25.00M | $1.97B |
| Q3 2021Sep 30, 2021 | $1.20B | $767.00M | $21.00M | $1.99B |
| Q2 2021Jun 30, 2021 | $1.23B | $699.00M | $20.00M | $1.95B |
| Q1 2021Mar 31, 2021 | $1.08B | $779.00M | $16.00M | $1.87B |
| Q4 2020Dec 31, 2020 | $978.00M | $806.00M | $23.00M | $1.81B |
| Q3 2020Sep 30, 2020 | $995.00M | $768.00M | $23.00M | $1.79B |
| Q2 2020Jun 30, 2020 | $882.00M | $649.00M | $17.00M | $1.55B |
| Q1 2020Mar 31, 2020 | $797.00M | $717.00M | $20.00M | $1.53B |
| Q4 2019Dec 31, 2019 | $784.00M | $868.00M | $22.00M | $1.67B |
| Q3 2019Sep 30, 2019 | $834.00M | $731.00M | $19.00M | $1.58B |
| Q2 2019Jun 30, 2019 | $798.00M | $724.00M | $25.00M | $1.55B |
| Q1 2019Mar 31, 2019 | $729.00M | $707.00M | $19.00M | $1.46B |
| Q4 2018Dec 31, 2018 | $664.00M | $872.00M | $28.00M | $1.56B |
| Q3 2018Sep 30, 2018 | $688.00M | $778.00M | $14.00M | $1.48B |
| Q2 2018Jun 30, 2018 | $671.00M | $734.00M | $16.00M | $1.42B |
| Q1 2018Mar 31, 2018 | $590.00M | $770.00M | $6.00M | $1.37B |
| Q4 2017Dec 31, 2017 | $561.00M | $891.00M | $8.00M | $1.46B |
| Q3 2017Sep 30, 2017 | $580.00M | $754.00M | $13.00M | $1.35B |
| Q2 2017Jun 30, 2017 | $568.00M | $689.00M | $23.00M | $1.28B |
| Q1 2017Mar 31, 2017 | $517.00M | $703.00M | $11.00M | $1.23B |
| Q4 2016Dec 31, 2016 | $477.00M | $790.00M | $10.00M | $1.28B |
| Q3 2016Sep 30, 2016 | $490.00M | $735.00M | $16.00M | $1.24B |
| Q2 2016Jun 30, 2016 | $523.00M | $673.00M | $12.00M | $1.21B |
| Q1 2016Mar 31, 2016 | $466.00M | $683.00M | $13.00M | $1.16B |
| Q4 2015Dec 31, 2015 | $457.00M | $803.00M | $14.00M | $1.27B |
| Q3 2015Sep 30, 2015 | $451.00M | $750.00M | $13.00M | $1.21B |
| Q2 2015Jun 30, 2015 | $471.00M | $690.00M | $14.00M | $1.18B |
| Q1 2015Mar 31, 2015 | $377.00M | $715.00M | $10.00M | $1.10B |
| Q4 2014Dec 31, 2014 | $405.00M | $904.00M | $11.00M | $1.32B |
| Q3 2014Sep 30, 2014 | $408.00M | $790.00M | $12.00M | $1.21B |
| Q2 2014Jun 30, 2014 | $439.00M | $703.00M | $16.00M | $1.16B |
| Q1 2014Mar 31, 2014 | $380.00M | $706.00M | $11.00M | $1.10B |
| Q4 2013Dec 31, 2013 | $405.00M | $849.00M | $16.00M | $1.27B |
| Q3 2013Sep 30, 2013 | $387.00M | $702.00M | $14.00M | $1.10B |
| Q2 2013Jun 30, 2013 | $435.00M | $667.00M | $12.00M | $1.11B |
| Q1 2013Jan 31, 2013 | $376.00M | $703.00M | $11.00M | $1.09B |
| Q4 2012Dec 31, 2012 | $385.00M | $791.00M | $0.00 | $1.18B |

